Abstract
Objectives: Describe the clinical, phenotypic, and genomic characteristics of ceftriaxone-resistance Neisseria gonorrhoeae from Scotland Methods: Cases were identified in routine care from 2018-2024. Minimum inhibitory concentrations were determined for seven antimicrobial agents. Whole genome sequencing was performed with Illumina and Oxford Nanopore Technology instruments. A phylogeny containing global ceftriaxone-resistant genomes was generated with Parsnp. A collection of ST8780 genomes was also analysed to give further context using reference based mapping with Snippy. Results: There were five cases of ceftriaxone-resistant N. gonorrhoeae detected. One case (MLST ST1903) clustered within the FC428 lineage in a returning traveller from an Asia-Pacific country. Two cases belonged to the recently described extensively drug resistant MLST ST16406, a returning traveller from an Asia-Pacific country and a sexual contact within Scotland. The final two cases were a resident of an Asia-Pacific country and a sexual contact within Scotland, both belonged to MLST ST8780. These were distinct from other publicly available ST8780 genomes suggesting a novel introduction of the mosaic penA 60.001 allele. All cases were initially treated with ceftriaxone-based regimes, four returned for test of cure and showed clearance of infection. Conclusions: As ceftriaxone resistance is increasingly identified, multiple public health interventions are required to reduce the impact of resistance on gonorrhoea treatment globally.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by NHS National Services Scotland via the Scottish Bacterial Sexually Transmitted Infections Reference Laboratory
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this work was granted by the Lothian National Research Scotland BioResource (Reference 20/ES/0061)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Further details on AMR mechanisms detected and NG-STAR types in the body of text, additon of clinical details as Table S3
Data Availability
Sequence data has been uploaded to the European Nucleotide Archive (BioProject PRJEB73456)
